| Literature DB >> 31284923 |
Homero San-Juan-Vergara1, Mark E Peeples2.
Abstract
Severe lower respiratory tract infection in infants and young children is most frequently caused by respiratory syncytial virus (RSV). RSV infects the smallest airways, making breathing difficult and in some infants requiring medical support. Severity is affected by viral dose, infant age, virus genotype, and effectiveness of the innate/adaptive immune responses. Severe disease correlates with later wheezing and asthma in some children. The adaptive immune response is protective but wanes after each infection, likely due to the ability of the RSV NS1/NS2 proteins to inhibit the innate immune response. Several vaccine approaches and candidates are currently in clinical trials.Entities:
Keywords: G protein; Genotypes; Neutralizing antibody; Postfusion; Prefusion; Respiratory syncytial virus (RSV); Vaccine
Mesh:
Substances:
Year: 2019 PMID: 31284923 PMCID: PMC6879194 DOI: 10.1016/j.iac.2019.04.001
Source DB: PubMed Journal: Immunol Allergy Clin North Am ISSN: 0889-8561 Impact factor: 3.479